Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Why this matters Lp(a) is a genetically determined, causal risk factor for ASCVD, yet targeted therapies are not yet widely available
External resources NEJM Phase 2 Trial: Triple Hormone Receptor Agonist Retatrutide for Obesity PMC Review: Retatrutide - A Game Changer in Obesity Pharmacotherapy ClinicalTrials.gov: Retatrutide TRIUMPH Clinical Trial Registry Nature Medicine: Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, personalized protocol builders, dosing calculators, and a community of thousands who have navigated these exact questions
Seven to twelve months post-treatment, 11 of 12 in the BPC157only group (~92%) and 3 of 4 in the combination group (~75%) reported significant pain relief
Results are gradual, so consistent use is important
Last Update: 03/25/2022
Wu F, Jacobs DR Jr, Daniels SR, et al
